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Pharmacogenomics aims to shed light on the role of genes and genomic variants in
clinical treatment response. Although, several drug–gene relationships are characterized
to date, many challenges still remain toward the application of pharmacogenomics
in the clinic; clinical guidelines for pharmacogenomic testing are still in their infancy,
whereas the emerging high throughput genotyping technologies produce a tsunami of
new findings. Herein, the potential of whole genome sequencing on pharmacogenomics
research and clinical application are highlighted.
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Introduction
Pharmacogenomics (PGx) aims to develop strategies for individualizing therapy to optimize drug
eﬃcacy andminimize toxicity on the basis of our improved understanding of how genomic variants
inﬂuence drug response. PGx research focuses on both pharmacodynamic and pharmacokinetic
eﬀects (Crews et al., 2012). Pharmacodynamic-PGx eﬀects correspond to diﬀerences in patient
response due to genomic variants in drug target pathways – or even, the drug targets themselves.
Pharmacokinetic-PGx eﬀects refer to diﬀerences in patient response because of genomic variants
in the pathways involved in drug metabolism or processing.
Pharmacogenomics research has exhibited a profound acceleration during the past decades
and the discovery and investigation of gene variants have followed several paths (Squassina et al.,
2010). This was made possible either by employing medical records (Neuraz et al., 2013), or adopt-
ing candidate gene and genome-wide association approaches (Wang and Weinshilboum, 2008;
Motsinger-Reif et al., 2013). Undoubtedly, the advent of next generation sequencing (NGS) has
created unprecedented opportunities towards the analysis of whole genomes, obtaining a full pic-
ture of people’s variomes. A variome refers to the set of genetic variations in populations of a single
species that have been acquired in a relatively short time on an evolutionary scale (Pavlopoulos
et al., 2013). To date, whole exome and/or whole genome sequencing can be easily performed using
several commercially available or proprietary platforms exhibiting a high degree of accuracy and at
a reasonable cost (Nekrutenko and Taylor, 2012).
Whole Genome Sequencing and PGx Challenges
Obtaining a full picture of a person’s variome is necessary, particularly in the case of
novel unique variants that may either render a drug metabolizing enzyme and/or trans-
porter inactive, or disable its expression and, hence, the carrier of the variant inter-
mediate or even poor metabolizer. NGS approaches are gradually being adopted for
PGx, involving either whole exome (Price et al., 2012) or whole genome sequencing
(Meyerson et al., 2010). For detecting DNA variants, whole exome sequencing is indeed a
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remarkable advance, yet an interim strategy, since, even if per-
fect technical accuracy is assumed, the exome comprises about
1% of the entire genome (Feero, 2014). Although several PGx
eﬀects are caused by amino-acid substitutions, PGx variants do
not necessarily occur within coding regions and in some cases,
not even within the genes themselves. Instead, it is well estab-
lished that variants that aﬀect transcript splicing or regulation of
transcription are also associated to PGx. Furthermore, population
based association studies have given rise to variants that may not
be causative, but can be statistically associated with the causative
marker(s) (Ardlie et al., 2002). To further complicate our choices,
whole exome sequencing is currently more cost-eﬀective, but
current capture probes can only target known exons, while regu-
latory and un-translated regions are not sequenced. Additionally,
there is a signiﬁcant bias (target enrichment step); capture probes’
eﬃciency varies considerably and hence, some sequences fail to
be targeted. Finally, the commercial target enrichment kits vary
considerably and as such, not all templates are sequenced with
equal eﬃciency. Consequently, a signiﬁcant proportion of vari-
ants may go undetected (Gamazon et al., 2012; Altman et al.,
2013).
There are very few whole genome sequencing studies in
PGx, despite the fact that genetic disorders have already begun
to greatly beneﬁt from whole genome sequencing applications.
Ashley et al. (2010) revealed gene variants suggestive of clopido-
grel resistance and positive response to lipid-lowering therapy,
indicating the need for a low initial dose for warfarin. In 2011,
a substantial amount of novel/uncharacterized variations (pre-
dicted to alter protein function) were obtained by whole genome
re-sequencing (Drögemöller et al., 2011). In another study that
involved 14,002 individuals, Nelson et al. (2012) explored rare
genetic variants by sequencing 202 genes encoding drug targets
and concluded that human populations harbor an abundance of
rare variants, many of which are deleterious and relate to dis-
ease risk. Drögemöller et al. (2013) performed a critical analysis
on the unmet needs of PGx research on schizophrenia show-
ing that there is a percentage of “inaccessible genome,” including
the CYP and HLA genes. Recently, whole genome sequencing
was exploited toward the identiﬁcation of novel and putatively
causative genomic variants, aﬀecting the structure and function
of 231 pharmacogenes in a large number of human genomes
from various ethnic backgrounds (Mizzi et al., 2014). In the same
study, the personalized PGx proﬁles of a seven-member family of
Greek origin were deﬁned and then, delineated with the antico-
agulation treatment response observed in two family members.
Whole Genome Sequencing for PGx in
the Clinic
Recent evidence, although limited at the present time, supports
the idea that whole genome sequencing is capable of revealing
unique (or rare) PGx markers that would otherwise go unde-
tected, if conventional genetic screeningmethods were employed.
Today, much of the challenges of whole genome sequenc-
ing to become clinically viable lie in (i) the costs of sequencing
technologies, (ii) the regulation scheme regarding the use of
(next-generation) sequencers as medical devices, (iii) setting up
a (centralized) whole genome sequencing facility, and (iv) train-
ing clinicians to interpret PGx data (Kampourakis et al., 2014;
Mooney, 2014). The current cost of whole genome sequencing by
which a comprehensive personalized PGxproﬁle will be obtained,
including almost all of the germline and de novo genomic variants
needed to manage all current and future treatment modalities
lies in the range of US$3000 and is declining. Hence, it is antic-
ipated that soon its cost eﬀectiveness will be appreciated, when
compared to the costs of testing for a single or several markers
in few pharmacogenes (from US$300 up to US$1500, respec-
tively; Fragoulakis et al., 2015). Recently, the Illumina MiSeqDx
sequencer was authorized by FDA (Sheridan, 2014), although the
sequencing coverage is particularly low (read length in paired
end run of 2◦×◦150 bp and hence, a 20× coverage for a 50 Mb
exome). This event raises great expectations toward the impact
of PGx tests in the clinic. While regulatory challenges are still
playing an evolving role in the application of PGx testing, sam-
ple outsourcing for data analysis, and interpretation might be the
answer to the obstacles of setting up a centralized whole genome
sequencing facility and clinicians’ training. Ultimately, it will only
be a matter of time until testing cost reimbursement is adopted by
national insurance bodies (Fragoulakis et al., 2015).
In light of the above, design and implementation of advanced
informatics solutions that ease to ﬁll-in the gap between PGx
research ﬁndings and clinical practice emerges as a major need.
In 2014, major – although, limited – milestones have been set.
eMERGE-PGx aims to (i) deploy PGRNseq, assessing sequence
variation in 84 pharmacogenes in 9,000 patients and several
clinical sites, (ii) integrate clinically validated PGx genotypes
into electronic health records (EHRs) with associated clinical
decision support, and (iii) develop a PGx variants’ repository
of unknown signiﬁcance linked to a repository of EHRs-based
clinical phenotype data for on-going PGx discovery (Rasmussen-
Torvik et al., 2014). Similar work was undertaken by our group,
which presented the development of an integrated electronic
‘PGx assistant,’ designed to provide personalized drug recom-
mendations based upon linked genotype-to-phenotype PGx data
and support biomedical researchers in the identiﬁcation of PGx-
related gene variants (Potamias et al., 2014), while the delineation
of genomic variants with rare drug outcomes is nowadays an
emerging research question in PGx and several groups and inter-
national consortia are gradually engaging to investigate this inter-
play (see www.genomicmedicinealliance.org). The latter would
only be possible through a whole genome sequencing approach.
Conclusion and Future Perspectives
As whole genome and/or whole exome sequencing approaches
begin to take hold in clinical care, not only how sequencing tech-
nologies evolve, but also how they get integrated into a clinical
setting are of utmost importance regarding the development of
PGx clinical tests and the understanding of the genetic eﬀects
on a prescription and treatment level that need to become more
readily available to the clinician. So far, the translation of PGx
research ﬁndings into clinical practice has been slow. The advent
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of whole genome sequencing technology will oﬀer an outstanding
potential toward the clinical application of PGx. Some key com-
ponents regarding successful clinical implementation have been
already addressed and actions have been already taken, whereas
others are to be met.
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